Semaglutide: An Opportunity or an Obstacle? A Case Report and Literature Review Exploring the Relationship Between the Popular Drug and Depression.

Introduction

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, was originally approved for the management of type 2 diabetes mellitus and has since received regulatory approval for weight management in adults with obesity or overweight with at least one comorbidity in the United States, Europe, the United Kingdom, and Canada.^1,2 As the prevalence of obesity continues to rise globally, the clinical adoption of GLP-1 receptor agonists has expanded substantially. Liraglutide, the only other GLP-1 analog with FDA approval for obesity (2014), exerts its appetite suppressing effects through central hypothalamic pathways, raising important questions about potential neuropsychiatric implications of this drug class.³

The most frequently reported adverse effects associated with semaglutide are gastrointestinal, including nausea, vomiting, diarrhea, and reduced appetite, with rare but serious adverse events including hepatobiliary disorders and acute pancreatitis.^1,4 While current pivotal clinical trials have not demonstrated significant psychiatric adverse effects with semaglutide compared to placebo, psychiatric events including suicidal ideation, have been documented with other agents in the GLP-1 receptor agonist class. Given that obese individuals carry a disproportionately higher burden of neuropsychiatric comorbidities and considering that this population is frequently excluded from major clinical trials, a thorough investigation of the neuropsychiatric safety of semaglutide remains a critical unmet need.

Methods

A comprehensive literature search was conducted across PubMed, Cochrane Library, and MEDLINE databases. Search terms included “semaglutide,” “GLP-1 receptor agonists,” “depression,” and “psychiatric effects,” used individually and in combination. Relevant case reports, observational studies, randomized controlled trials, and systematic reviews published in English were included. Reference lists of retrieved articles were manually reviewed for additional relevant sources.

Case Presentation

A 57-year-old female with a well-established psychiatric history of recurrent major depressive disorder (MDD) and a medical history significant for obesity presented for psychiatric evaluation with a six-month history of worsening depressive symptoms. She reported that approximately four months prior to presentation, she had been initiated on one weekly subcutaneous semaglutide for weight management, during which she achieved a weight loss of approximately 20 lbs.

Since initiating semaglutide therapy, the patient described a marked decline in appetite, which she attributed primarily to the medication. She concurrently reported symptoms consistent with impaired gastric motility, including persistent nausea and constipation, which she indicated had significantly compounded her emotional distress and low mood. Notably, she denied any prior history of GI disorders or analogous symptoms preceding semaglutide initiation.

Upon evaluation, the patient’s depressive symptoms were assessed as consistent with a relapse of MDD in the context of ongoing semaglutide use and associated GI adverse effects. Vortioxetine, a multimodal serotonergic antidepressant, was added to her existing treatment regimen to specifically target her depressive symptomatology.

At the four week follow-up visit, the patient reported only mild improvement in mood. GI symptoms persisted without meaningful resolution and continued to adversely affect her emotional well-being and daily functioning. She remained on semaglutide, as the weight loss benefit was deemed clinically significant by her treating physician.

Discussion

This case highlights a potential, though not yet definitively established, association between semaglutide use and the exacerbation of depressive symptoms in a patient with pre-existing MDD. While current large scale randomized controlled trials, including the STEP program have not identified statistically significant psychiatric adverse effects with semaglutide compared to placebo,^2,5 the clinical picture presented here raises important questions about the vulnerability of individuals with neuropsychiatric histories to mood related sequelae.

Liraglutide, the predecessor GLP-1 analog approved for obesity, has been associated with depression and suicidal ideation in select reports and post marketing surveillance data.³ These findings suggest that the central nervous system activity shared among GLP-1 receptor agonists particularly their role in appetite regulation via hypothalamic pathways may serve as a biological substrate for mood dysregulation in predisposed individuals. The observed relationship between appetite suppression and mood disturbance parallels historical precedents in anti-obesity pharmacotherapy: several agents previously approved for clinical use, including rimonabant, sibutramine, and fenfluramine, were ultimately withdrawn from global and regional markets due to psychiatric adverse effects, cardiotoxicity, or dependency profiles.⁵

In this patient, the persistent GI adverse effects namely nausea, constipation, and anorexia may have functioned as a physiological stressor compounding her vulnerability to depressive relapse. The bidirectional relationship between the gut and brain, mediated in part through the gut brain axis and enteroendocrine signaling, may further contextualize the intersection of GI symptomatology and mood dysregulation observed in this case.

A significant limitation in the current evidence base is the systematic exclusion of individuals with neuropsychiatric disorders from pivotal clinical trials of semaglutide. Given that obesity is associated with a substantially higher prevalence of depression, anxiety, and other neuropsychiatric conditions relative to the general population, this exclusion creates a critical evidence gap with direct implications for real world prescribing. As semaglutide continues to be adopted at scale, clinicians must maintain vigilance for the emergence or worsening of psychiatric symptoms, particularly in patients with pre-existing mental health conditions.

Conclusion

This case report underscores the importance of proactive neuropsychiatric monitoring in patients initiated on semaglutide, particularly those with a history of MDD or other psychiatric conditions. Although a causal relationship between semaglutide and depression cannot be established from a single case, the temporal association and plausible biological mechanisms warrant serious consideration. Future prospective studies should explicitly include patients with neuropsychiatric comorbidities to fully characterize the psychiatric safety profile of this rapidly expanding drug class. A comprehensive understanding of the long-term effects of semaglutide on social, mental, and physical health is essential to inform evidence based, patient centered prescribing decisions.

Conflicts of Interest

The authors declare no conflicts of interest.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not for profit sectors.